- A clinician-derived, 5-point global assessment and body surface area (SGAxBSA) tool appears valid and feasible for signs of atopic dermatitis (AD) in clinical practice.
Why this matters
- Current instruments for signs of AD may not be suitable for clinical practice because of their complexity.
- SGAxBSA score was significantly correlated with the Eczema Area and Severity Index (r=0.91), average daily pruritus (r=0.71), and patient global assessment (r=0.74).
- SGAxBSA score also was correlated with a derived global scale comprising the average of 4 signs rated between 0 and 3 (r=0.77; P<.0001 for all>
- Acceptability, responsiveness, and floor or ceiling effects of SGAxBSA were classified as adequate.
- Severity banding was maximized at 1, 21, and 87 (κ=0.4902).
- 138 patients with AD (325 total clinic visits) were included.
- Funding: None.